Lab members

Group leader : Pr. Laurence ZITVOGEL

• Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Tumour immunology and immunotherapy

Group 1 of the Inserm (National Institute of Health and Medical Research) UMR 1015 research unit, « Tumour immunology and immunotherapy of cancer », is under the direction of Professor Laurence Zitvogel.  Between 2015 and 2018 it will be exploring three lines of research: 
-    Gut microbiota and pro- or anti-tumour inflammatory/immunological activity, by measuring the effect of specific therapies on their regulation, 

Lab members

• Clara Nahmias (DR CNRS, HDR)
• Adam Telerman (MD, DRCN CNRS)
• Olivia Fromigué (CRCN-HDR INSERM)
• Anna Rocca (CRCN CNRS)
• Robert Amson (MD, researcher)
• Sylvie Rodrigues-Ferreira (researcher, Innovarion)
• Catherine Genestie (Pathologist, GRCC)
• Magali Lacroix-Triki (MD, PhD, Pathologist)
• Alexandra Leary (MD, PhD, GRCC)
• Etienne Rouleau (MD, PhD, GRCC)
• Inés Vaz-Luis (MD, PhD)
• Jean-Charles Ahomadegbe (MCU Amiens, HDR)
• Tony Sourisseau (Engineer, GRCC)